Cyclophosphamide

  • Update of EULAR recommendations for the treatment of systemic sclerosis
    Otylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, Mike Becker, Agnieszka Kulak, Yannick Allanore, Oliver Distler, Philip Clements, Maurizio Cutolo, Laszlo Czirjak, Nemanja Damjanov, Francesco del Galdo, Christopher P Denton, Jörg H W Distler, Ivan Foeldvari, Kim Figelstone, Marc Frerix, Daniel E Furst, Serena Guiducci, Nicolas Hunzelmann, Dinesh Khanna, Marco Matucci-Cerinic, Ariane L Herrick, Frank van den Hoogen, Jacob M van Laar, Gabriela Riemekasten, Richard Silver, Vanessa Smith, Alberto Sulli, Ingo Tarner, Alan Tyndall, Joep Welling, Frederic Wigley, Gabriele Valentini, Ulrich A Walker, Francesco Zulian, Ulf Müller-Ladner
  • Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
    Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, Mark Lunt, Roger Hesselstrand, Luc Mouthon, Alan Silman, Edith Brown, László Czirják, Jörg H W Distler, Oliver Distler, Kim Fligelstone, William J Gregory, Rachel Ochiel, Madelon Vonk, Codrina Ancuţa, Voon H Ong, Dominique Farge, Marie Hudson, Marco Matucci-Cerinic, Alexandra Balbir-Gurman, Øyvind Midtvedt, Alison C Jordan, Paresh Jobanputra, Wendy Stevens, Pia Moinzadeh, Frances C Hall, Christian Agard, Marina E Anderson, Elisabeth Diot, Rajan Madhok, Mohammed Akil, Maya H Buch, Lorinda Chung, Nemanja Damjanov, Harsha Gunawardena, Peter Lanyon, Yasmeen Ahmad, Kuntal Chakravarty, Søren Jacobsen, Alexander J MacGregor, Neil McHugh, Ulf Müller-Ladner, Gabriela Riemekasten, Michael Becker, Janet Roddy, Patricia E Carreira, Anne Laure Fauchais, Eric Hachulla, Jennifer Hamilton, Murat İnanç, John S McLaren, Jacob M van Laar, Sanjay Pathare, Susannah Proudman, Anna Rudin, Joanne Sahhar, Brigitte Coppere, Christine Serratrice, Tom Sheeran, Douglas J Veale, Claire Grange, Georges-Selim Trad, Christopher P Denton
  • Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
    Emma E van Daalen, Raffaella Rizzo, Andreas Kronbichler, Ron Wolterbeek, Jan A Bruijn, David R Jayne, Ingeborg M Bajema, Chinar Rahmattulla
  • EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
    M Yates, R A Watts, I M Bajema, M C Cid, B Crestani, T Hauser, B Hellmich, J U Holle, M Laudien, M A Little, R A Luqmani, A Mahr, P A Merkel, J Mills, J Mooney, M Segelmark, V Tesar, K Westman, A Vaglio, N Yalçındağ, D R Jayne, C Mukhtyar
  • Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type
    Sebastian Unizony, Miguel Villarreal, Eli M Miloslavsky, Na Lu, Peter A Merkel, Robert Spiera, Philip Seo, Carol A Langford, Gary S Hoffman, CG M Kallenberg, E William St. Clair, David Ikle, Nadia K Tchao, Linna Ding, Paul Brunetta, Hyon K Choi, Paul A Monach, Fernando Fervenza, John H Stone, Ulrich Specks
  • Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions
    Md Yuzaiful Md Yusof, Edward M Vital, Sudipto Das, Shouvik Dass, Gururaj Arumugakani, Sinisa Savic, Andrew C Rawstron, Paul Emery
  • Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
    Rachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, Thomas Hauser, Raashid Luqmani, Matthew D Morgan, Chen Au Peh, Caroline O Savage, Marten Segelmark, Vladimir Tesar, Pieter van Paassen, Michael Walsh, Kerstin Westman, David RW Jayne, for the European Vasculitis Society (EUVAS)
  • Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
    Cees G M Kallenberg
  • Recent progress in conventional and biologic therapy for systemic lupus erythematosus
    David Wofsy